Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis

Oncogene

Volumn 32, Issue 2, 2013, Pages 160-170

  Wen, Z H ^a   Su, Y C ^a   Lai, P L ^a   Zhang, Y ^a   Xu, Y F ^a   Zhao, A ^b   Yao, G Y ^a   Jia, C H ^a   Lin, J ^a   Xu, S ^a   Wang, L ^a   Wang, X K ^a   Liu, A L ^a   Jiang, Y ^c   Dai, Y F ^b   Bai, X C ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

angiogenesis; arachidonic acid; breast cancer; mammalian target of rapamycin; tumorigenesis

Indexed keywords

ARACHIDONIC ACID; CYCLOOXYGENASE 2; CYTOSOLIC PHOSPHOLIPASE A2; LIPOXYGENASE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN KINASE B; RAPAMYCIN; RAPTOR ASSOCIATION IN RAS HOMOLOG ENRICHED IN BRAIN PROTEIN; TUBERIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANIMALS; ARACHIDONIC ACID; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHICK EMBRYO; CYCLOOXYGENASE 2; FEMALE; HUMANS; LIPOXYGENASE; MCF-7 CELLS; MULTIPROTEIN COMPLEXES; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOLIPASES A2; PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; MAMMALIA; RAPTORES; RATTUS;

EID: 84872171596     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.47     Document Type: Article

References (51)

1. Chen X, Sood S, Yang CS, Li N, Sun Z. Five-lipoxygenase pathway of arachidonic acid metabolism in carcino-genesis and cancer chemoprevention. Curr Cancer Drug Targets 2006; 6: 613-622. (Pubitemid 44691003)
2. Horn L, Backlund M, Johnson DH. Targeting the eicosanoid pathway in nonsmall-cell lung cancer. Expert Opin Ther Targets 2009; 13: 675-688.
3. Harizi H, Corcuff JB, Gualde N. Arachidonic-Acid-derived eicosanoids: Roles in biology and immunopathology. Trends Mol Med 2008; 14: 461-469.
4. Kim C, Kim JY, Kim JH. Cytosolic phospholipase A(2), lipoxygenase metabolites, and reactive oxygen species. BMB Rep 2008; 41: 555-559.
5. Nakanishi M, Rosenberg DW. Roles of cPLA2alpha and arachidonic acid in cancer. Biochim Biophys Acta 2006; 1761: 1335-1343. (Pubitemid 44738711)
6. Menna C, Olivieri F, Catalano A, Procopio A. Lipoxygenase inhibitors for cancer prevention: Promises and risks. Curr Pharm Des 2010; 16: 725-733.
7. Agrawal A, Fentiman IS. NSAIDs and breast cancer: A possible prevention and treatment strategy. Int J Clin Pract 2008; 62: 444-449. (Pubitemid 351197419)
8. Singh-Ranger G, Salhab M, Mokbel K. The role of cyclooxygenase-2 in breast cancer: Review. Breast Cancer Res Treat 2008; 109: 189-198. (Pubitemid 351644840)
9. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: Promise, perils and pharmacogenetics. Nat Rev Cancer 2006; 6: 130-140. (Pubitemid 43361545)
10. Jiang WG, Douglas-Jones AG, Mansel RE. Aberrant expression of 5-lipoxygenaseactivating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer. Prostaglandins Leukot Essent Fatty Acids 2006; 74: 125-134. (Pubitemid 43082137)
11. McCormick DL, Spicer AM. Nordihydroguaiaretic acid suppression of rat mammary carcinogenesis induced by N-methyl-N-nitrosourea. Cancer Lett 1987; 37: 139-146. (Pubitemid 17157832)
12. Navarro-Tito N, Robledo T, Salazar EP. Arachidonic acid promotes FAK activation and migration in MDA-MB-231 breast cancer cells. Exp Cell Res 2008; 314: 3340-3355.
13. Kennett SB, Roberts JD, Olden K. Requirement of protein kinase C micro activation and calpain-mediated proteolysis for arachidonic acid-stimulated adhesion of MDA-MB-435 human mammary carcinoma cells to collagen type IV. J Biol Chem 2004; 279: 3300-3307. (Pubitemid 38140564)
14. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010; 40: 310-322.
15. Bai X, Jiang Y. Key factors in mTOR regulation. Cell Mol Life Sci 2010; 67: 239-253.
16. Zoncu R, Efeyan A, Sabatini DM. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35.
17. Foster KG, Fingar DC. Mammalian target of rapamycin (mTOR): Conducting the cellular signaling symphony. J Biol Chem 2010; 285: 14071-14077.
18. Efeyan A, Sabatini DM. mTOR and cancer: Many loops in one pathway. Curr Opin Cell Biol 2010; 22: 169-176.
19. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22. (Pubitemid 47001784)
20. Martinez-Orozco R, Navarro-Tito N, Soto-Guzman A, Castro-Sanchez L, Perez Salazar E. Arachidonic acid promotes epithelial-to-mesenchymal-like transition in mammary epithelial cells MCF10A. Eur J Cell Biol 2010; 89: 476-488.
21. Pidgeon GP, Lysaght J, Krishnamoorthy S, Reynolds JV, O'Byrne K, Nie D et al. Lipoxygenase metabolism: Roles in tumor progression and survival. Cancer Metastasis Rev 2007; 26: 503-524. (Pubitemid 350115127)
22. Hynes NE, Boulay A. The mTOR pathway in breast cancer. J Mammary Gland Biol Neoplasia 2006; 11: 53-61. (Pubitemid 44309189)
23. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6: 1122-1128. (Pubitemid 39468014)
24. Razanamahefa L, Prouff S, Bardon S. Stimulatory effect of arachidonic acid on T-47D human breast cancer cell growth is associated with enhancement of cyclin D1 mRNA expression. Nutr Cancer 2000; 38: 274-280. (Pubitemid 32762028)
25. Cakir Y, Plummer III HK, Tithof PK, Schuller HM. Beta-Adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines. Int J Oncol 2002; 21: 153-157.
26. Zhang B, Cao H, Rao GN. Fibroblast growth factor-2 is a downstream mediator of phosphatidylinositol 3-kinase-Akt signaling in 14,15- epoxyeicosatrienoic acid-induced angiogenesis. J Biol Chem 2006; 281: 905-914.
27. Zhang B, Cao H, Rao GN. 15(S)-hydroxyeicosatetraenoic acid induces angiogenesis via activation of PI3K-Akt-mTOR-S6K1 signaling. Cancer Res 2005; 65: 7283-7291. (Pubitemid 41161260)
28. Yecies JL, Manning BD. mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med 2011; 89: 221-228.
29. Mieulet V, Lamb RF. Tuberous sclerosis complex: Linking cancer to metabolism. Trends Mol Med 2010; 16: 329-335.
30. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008; 320: 1496-1501. (Pubitemid 351929429)
31. Goberdhan DC. Intracellular amino acid sensing and mTORC1-regulated growth: New ways to block an old targetCurr Opin Investig Drugs 2010; 11: 1360-1367.
32. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110: 163-175. (Pubitemid 34876545)
33. Duan S, Skaar JR, Kuchay S, Toschi A, Kanarek N, Ben-Neriah Y et al. mTOR generates an auto-Amplification loop by triggering the betaTrCP-And CK1alphadependent degradation of DEPTOR. Mol Cell 2011; 44: 317-324.
34. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009; 137: 873-886.
35. Holmes MD, Hunter DJ, Colditz GA, Stampfer MJ, Hankinson SE, Speizer FE et al. Association of dietary intake of fat and fatty acids with risk of breast cancer. JAMA 1999; 281: 914-920. (Pubitemid 29124635)
36. Thiebaut AC, Chajes V, Gerber M, Boutron-Ruault MC, Joulin V, Lenoir G et al. Dietary intakes of omega-6 and omega-3 polyunsaturated fatty acids and the risk of breast cancer. Int J Cancer 2009; 124: 924-931.
37. Yamashita S, Yamashita J, Ogawa M. Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency. Br J Cancer 1994; 69: 1166-1170. (Pubitemid 24161881)
38. Ye YN, Wu WK, Shin VY, Bruce IC, Wong BC, Cho CH. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 2005; 26: 827-834. (Pubitemid 41214346)
39. Paine E, Palmantier R, Akiyama SK, Olden K, Roberts JD. Arachidonic acid activates mitogen-Activated protein (MAP) kinase-Activated protein kinase 2 and mediates adhesion of a human breast carcinoma cell line to collagen type IV through a p38 MAP kinase-dependent pathway. J Biol Chem 2000; 275: 11284-11290. (Pubitemid 30212776)
40. Navarro-Tito N, Soto-Guzman A, Castro-Sanchez L, Martinez-Orozco R, Salazar EP. Oleic acid promotes migration on MDA-MB-231 breast cancer cells through an arachidonic acid-dependent pathway. Int J Biochem Cell Biol 2010; 42: 306-317.
41. Buzzard CJ, Pfister SL, Campbell WB. Endothelium-dependent contractions in rabbit pulmonary artery are mediated by thromboxane A2. Circ Res 1993; 72: 1023-1034. (Pubitemid 23105508)
42. Zhou L, Vessby B, Nilsson A. Quantitative role of plasma free fatty acids in the supply of arachidonic acid to extrahepatic tissues in rats. J Nutr 2002; 132: 2626-2631. (Pubitemid 35013246)
43. Hyde CA, Missailidis S. Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-Angiogenesis. Int Immunopharmacol 2009; 9: 701-715.
44. Linkous AG, Yazlovitskaya EM, Hallahan DE. Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis. J Natl Cancer Inst 2010; 102: 1398-1412.
45. Meyer AM, Dwyer-Nield LD, Hurteau GJ, Keith RL, O'Leary E, You M et al. Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. Carcinogenesis 2004; 25: 1517-1524. (Pubitemid 39162717)
46. Weiser-Evans MC, Wang XQ, Amin J, Van Putten V, Choudhary R, Winn RA et al. Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis. Cancer Res 2009; 69: 1733-1738.
47. Kuehn HS, Jung MY, Beaven MA, Metcalfe DD, Gilfillan AM. Prostaglandin E2 activates and utilizes mTORC2 as a central signaling locus for the regulation of mast cell chemotaxis and mediator release. J Biol Chem 2011; 286: 391-402.
48. Camp RL, Rimm EB, Rimm DL. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 1999; 86: 2259-2265. (Pubitemid 30010366)
49. Li M, Zhao L, Liu J, Liu A, Jia C, Ma D et al. Multi-mechanisms are involved in reactive oxygen species regulation of mTORC1 signaling. Cell Signal 2010; 22: 1469-1476.
50. Bai X, Ma D, Liu A, Shen X, Wang QJ, Liu Y et al. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 2007; 318: 977-980. (Pubitemid 350098994)
51. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159-168.